Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating reiterated by investment analysts at Jefferies Group LLC in a research note issued on Thursday. They presently have a $65.00 target price on the healthcare product maker’s stock. Jefferies Group LLC’s price objective indicates a potential upside of 15.41% from the company’s previous close. Jefferies Group also issued estimates for Abbott Laboratories’ Q1 2018 earnings at $0.58 EPS, Q2 2018 earnings at $0.72 EPS, Q3 2018 earnings at $0.76 EPS and Q4 2018 earnings at $0.79 EPS.

A number of other analysts have also recently weighed in on ABT. BTIG Research started coverage on shares of Abbott Laboratories in a research note on Wednesday, June 21st. They issued a “buy” rating and a $56.00 target price on the stock. Guggenheim started coverage on shares of Abbott Laboratories in a research note on Thursday, June 29th. They issued a “buy” rating and a $58.00 target price on the stock. Wells Fargo & Company reissued an “outperform” rating and issued a $54.00 target price (up previously from $47.50) on shares of Abbott Laboratories in a research note on Friday, June 30th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Monday, July 3rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating on shares of Abbott Laboratories in a research note on Monday, July 10th. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $56.81.

Shares of Abbott Laboratories (NYSE:ABT) traded up 0.57% during trading on Thursday, reaching $56.32. The company’s stock had a trading volume of 5,528,681 shares. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $56.60. The company’s 50-day moving average price is $53.27 and its 200 day moving average price is $48.51. The stock has a market capitalization of $97.85 billion, a price-to-earnings ratio of 78.88 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 14.50%. The firm’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. Analysts anticipate that Abbott Laboratories will post $2.50 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Jefferies Group LLC Reaffirms “Buy” Rating for Abbott Laboratories (ABT)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/22/jefferies-group-llc-reaffirms-buy-rating-for-abbott-laboratories-abt.html.

In other news, insider Sharon J. Bracken sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total transaction of $98,320.00. Following the transaction, the insider now directly owns 28,806 shares in the company, valued at $1,416,102.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen R. Fussell sold 196,550 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the transaction, the insider now owns 221,488 shares in the company, valued at $10,963,656. The disclosure for this sale can be found here. Insiders have sold 333,310 shares of company stock worth $16,857,255 over the last quarter. 0.76% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Sanders Morris Harris LLC lifted its holdings in Abbott Laboratories by 0.3% in the second quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after buying an additional 16 shares during the period. St. Louis Trust Co lifted its holdings in Abbott Laboratories by 0.4% in the second quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock valued at $238,000 after buying an additional 20 shares during the period. Alpha Windward LLC lifted its holdings in Abbott Laboratories by 0.6% in the second quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock valued at $264,000 after buying an additional 30 shares during the period. Lakeview Capital Partners LLC lifted its holdings in Abbott Laboratories by 0.6% in the second quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock valued at $277,000 after buying an additional 33 shares during the period. Finally, Johanson Financial Advisors Inc. lifted its holdings in Abbott Laboratories by 0.5% in the second quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after buying an additional 37 shares during the period. Institutional investors own 71.45% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.